[开放获取]   从发病机制认知变化看慢性自发性荨麻疹治疗进展

doi:10.35541/cjd.20230102

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (6): 552-558.doi: 10.35541/cjd.20230102

[开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展

梁云生^1，2 黎展宏^1，2 伍奕蓓¹

¹南方医科大学皮肤病医院，广州 510091；²安徽医科大学广东皮肤病临床学院，广州 510091

收稿日期:2023-02-24 修回日期:2023-04-02 发布日期:2023-06-05
通讯作者: 梁云生 E-mail:yunshengliang@aliyun.com
基金资助:
国家自然科学基金（81972941）；广东省自然科学基金（2019A1515011561）

Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis

Liang Yunsheng^1,2, Li Zhanhong^1,2, Wu Yibei¹

¹Dermatology Hospital of Southern Medical University, Guangzhou 510091, China; ²Guangdong Clinical College of Dermatology, Anhui Medical University, Guangzhou 510091, China

Received:2023-02-24 Revised:2023-04-02 Published:2023-06-05
Contact: Liang Yunsheng E-mail:yunshengliang@aliyun.com
Supported by:
National Natural Science Foundation of China （81972941）; Guangdong Provincial Natural Science Foundation （2019A1515011561）

摘要/Abstract

摘要： 【摘要】慢性自发性荨麻疹病理机制复杂，自身抗体、炎症细胞、凝血与补体系统等均可参与疾病的发生发展，但肥大细胞在其中居于中心地位。随着对其发病机制研究的深入，药物研究更加注重于调控肥大细胞的病理状态。本文就慢性自发性荨麻疹发病机制、治疗药物进展做一综述。

关键词: 荨麻疹, 肥大细胞, 免疫球蛋白E, 诊断, 治疗, 慢性自发性荨麻疹, 发病机制

Abstract: 【Abstract】 Mast cells, autoantibodies, inflammatory cells, coagulation cascade, complement system and nervous system are all involved in the complex pathogenesis of chronic spontaneous urticaria （CSU）, while mast cells play a pivotal role in it. With deeper understanding of the pathogenesis of CSU, cutting-edge therapeutic methods are gradually being used in clinical practice. Nowadays, pharmacotherapyeutic studies are more focused on accurately modulating the pathological state of mast cells. This review summarizes recent advances in the pathogenesis of and medicines for CSU.

Key words: Urticaria, Mast cells, Immunoglobulin E, Diagnosis, Treatment, Chronic spontaneous urticaria, Pathogenesis

梁云生黎展宏伍奕蓓. [开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展[J]. 中华皮肤科杂志, 2023,56(6):552-558. doi:10.35541/cjd.20230102

Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis[J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558.doi:10.35541/cjd.20230102

参考文献 38

［1］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2022版）［J］. 中华皮肤科杂志, 2022,55（12）:1041⁃1049. doi: 10.35541/cjd.20220609.
［2］	Zuberbier T, Bindslev⁃Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: management of urticaria［J］. Allergy, 2006,61（3）:321⁃331. doi: 10.1111/j.1398⁃9995.2005.00962.x.
［3］	Zuberbier T, Asero R, Bindslev⁃Jensen C, et al. EAACI/GA（2）LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria［J］. Allergy, 2009,64（10）:1417⁃1426. doi: 10.1111/j.1398⁃9995.2009.02179.x.
［4］	Zuberbier T, Aberer W, Asero R, et al. Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2014,69（7）:e1⁃e29. doi: 10.1111/all.12370.
［5］	Kolkhir P, Giménez⁃Arnau AM, Kulthanan K, et al. Urticaria［J］. Nat Rev Dis Primers, 2022,8（1）:61. doi: 10.1038/s41572⁃022⁃00389⁃z.
［6］	Giménez⁃Arnau AM, DeMontojoye L, Asero R, et al. The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells［J］. J Allergy Clin Immunol Pract, 2021,9（6）:2195⁃2208. doi: 10.1016/j.jaip.2021.03.033.
［7］	Maurer M, Eyerich K, Eyerich S, et al. Urticaria: Collegium Internationale Allergologicum（CIA）update 2020［J］. Int Arch Allergy Immunol, 2020,181（5）:321⁃333. doi: 10.1159/000507218.
［8］	Maurer M, Khan DA, Elieh Ali Komi D, et al. Biologics for the use in chronic spontaneous urticaria: when and which［J］. J Allergy Clin Immunol Pract, 2021,9（3）:1067⁃1078. doi: 10.1016/ j.jaip.2020.11.043.
［9］	Altrichter S, Zampeli V, Ellrich A, et al. IgM and IgA in addition to IgG autoantibodies against FcɛRIα are frequent and associated with disease markers of chronic spontaneous urticaria［J］. Allergy, 2020,75（12）:3208⁃3215. doi: 10.1111/all.14412.
［10］	Curto⁃Barredo L, Pujol RM, Roura⁃Vives G, et al. Chronic urticaria phenotypes: clinical differences regarding triggers, activity, prognosis and therapeutic response［J］. Eur J Dermatol, 2019,29（6）:627⁃635. doi: 10.1684/ejd.2019.3674.
［11］	Hershko AY, Rivera J. Mast cell and T cell communication; amplification and control of adaptive immunity［J］. Immunol Lett, 2010,128（2）:98⁃104. doi: 10.1016/j.imlet.2009.10.013.
［12］	Zhou B, Li J, Liu R, et al. The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria［J］. Front Immunol, 2022,13:879754. doi: 10.3389/fimmu.2022.879754.
［13］	Yanase Y, Takahagi S, Ozawa K, et al. The role of coagulation and complement factors for mast cell activation in the pathogenesis of chronic spontaneous urticaria［J］. Cells, 2021,10（7）:1759. doi: 10.3390/cells10071759.
［14］	Shtessel M, Limjunyawong N, Oliver ET, et al. MRGPRX2 activation causes increased skin reactivity in patients with chronic spontaneous urticaria［J］. J Invest Dermatol, 2021,141（3）:678⁃681.e2. doi: 10.1016/j.jid.2020.06.030.
［15］	Cao C, Roth BL. The structure, function, and pharmacology of MRGPRs［J］. Trends Pharmacol Sci, 2023,44（4）:237⁃251. doi: 10.1016/j.tips.2023.02.002.
［16］	Melikoglu M, Pala E, Bayraktar M. Etiological causes in patients with acute urticaria and angioedema: a cross⁃sectional study［J］. Allergol Immunopathol （Madr）, 2022,50（S Pt 2）:15⁃23. doi: 10.15586/aei.v50iSP2.784.
［17］	Liu ZQ, Li XX, Qiu SQ, et al. Vitamin D contributes to mast cell stabilization［J］. Allergy, 2017,72（8）:1184⁃1192. doi: 10.1111/all.13110.
［18］	Matsuo H, Yokooji T, Morita H, et al. Aspirin augments IgE⁃mediated histamine release from human peripheral basophils via Syk kinase activation［J］. Allergol Int, 2013,62（4）:503⁃511. doi: 10.2332/allergolint.13⁃OA⁃0536.
［19］	Chompunud Na Ayudhya C, Ali H. Mas⁃related G protein⁃coupled receptor⁃X2 and its role in non⁃immunoglobulin E⁃mediated drug hypersensitivity［J］. Immunol Allergy Clin North Am, 2022,42（2）:269⁃284. doi: 10.1016/j.iac.2021.12.003.
［20］	Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2022,77（3）:734⁃766. doi: 10.1111/all. 15090.
［21］	Engeroff P, Vogel M. The role of CD23 in the regulation of allergic responses［J］. Allergy, 2021,76（7）:1981⁃1989. doi: 10.1111/all.14724.
［22］	中华医学会皮肤性病学分会荨麻疹研究中心. 抗IgE疗法——奥马珠单抗治疗慢性荨麻疹专家共识［J］. 中华皮肤科杂志, 2021,54（12）:1057⁃1062. doi: 10.35541/cjd.20210568.
［23］	张宇, 高迎霞, 顾宁琰, 等. 奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析［J］. 中华皮肤科杂志, 2021,54（7）:582⁃585. doi: 10.35541/cjd.20201261.
［24］	Sussman G, Hébert J, Gulliver W, et al. Omalizumab re⁃treatment and step⁃up in patients with chronic spontaneous urticaria: OPTIMA Trial［J］. J Allergy Clin Immunol Pract, 2020,8（7）:2372⁃2378.e5. doi: 10.1016/j.jaip.2020.03.022.
［25］	云玉会. 奥马珠单抗治疗慢性荨麻疹的真实世界数据的研究［D］.合肥: 安徽医科大学, 2022. doi: 10.26921/d.cnki.ganyu. 2022.000760.
［26］	Harrison CA, Bastan R, Peirce MJ, et al. Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506［J］. Br J Pharmacol, 2007,150（4）:509⁃518. doi: 10.1038/sj.bjp.0707002.
［27］	Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria: a meta⁃analysis and systematic review［J］. J Allergy Clin Immunol Pract, 2018,6（2）:586⁃599. doi: 10.1016/j.jaip.2017.07.017.
［28］	Thurmond RL. The histamine H4 receptor: from orphan to the clinic［J］. Front Pharmacol, 2015,6:65. doi: 10.3389/fphar.2015. 00065.
［29］	Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti⁃IgE antibody ligelizumab differs from omalizumab［J］. Nat Commun, 2020,11（1）:165. doi: 10.1038/s41467⁃019⁃13815⁃w.
［30］	Kuo BS, Li CH, Chen JB, et al. IgE⁃neutralizing UB⁃221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23⁃mediated IgE downregulation and relieves urticaria symptoms［J］. J Clin Invest, 2022,132（15）:e157765. doi: 10.1172/JCI15 7765.
［31］	Sun Y, Lin SY, Lan CE. Dupilumab as a rescue therapy for a chronic urticaria patient who showed secondary failure to omalizumab［J］. Kaohsiung J Med Sci, 2022,38（6）:610⁃611. doi: 10.1002/kjm2.12531.
［32］	Metz M, Sussman G, Gagnon R, et al. Fenebrutinib in H1 antihistamine⁃refractory chronic spontaneous urticaria: a randomized phase 2 trial［J］. Nat Med, 2021,27（11）:1961⁃1969. doi: 10.1038/s41591⁃021⁃01537⁃w.
［33］	Ramirez Molina C, Falkencrone S, Skov PS, et al. GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin［J］. Br J Pharmacol, 2019,176（8）:1135⁃1142. doi: 10.1111/bph.14610.
［34］	Wilson LH, Eliason MJ, Leiferman KM, et al. Treatment of refractory chronic urticaria with tumor necrosis factor⁃alfa inhibitors［J］. J Am Acad Dermatol, 2011,64（6）:1221⁃1222. doi: 10.1016/j.jaad.2009.10.043.
［35］	Sabag DA, Matanes L, Bejar J, et al. Interleukin⁃17 is a potential player and treatment target in severe chronic spontaneous urticaria［J］. Clin Exp Allergy, 2020,50（7）:799⁃804. doi: 10. 1111/cea.13616.
［36］	Bernstein JA, Singh U, Rao MB, et al. Benralizumab for chronic spontaneous urticaria［J］. N Engl J Med, 2020,383（14）:1389⁃1391. doi: 10.1056/NEJMc2016395.
［37］	Altrichter S, Staubach P, Pasha M, et al. An open⁃label, proof⁃of⁃concept study of lirentelimab for antihistamine⁃resistant chronic spontaneous and inducible urticaria［J］. J Allergy Clin Immunol, 2022,149（5）:1683⁃1690.e7. doi: 10.1016/j.jaci.2021.12.772.
［38］	Terhorst⁃Molawi D, Hawro T, Grekowitz E, et al. Anti⁃KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria［J］. Allergy, 2022. doi: 10.1111/all.15585.

[1]	陈奇权杨显杰顾恒徐金华郝飞姚煦宋志强. [开放获取] 基于德尔菲法构建《中国慢性诱导性荨麻疹诊治专家共识（2023）》[J]. 中华皮肤科杂志, 2023, 56(6): 534-539.
[2]	中华医学会皮肤性病学分会免疫学组. [开放获取] 中国慢性诱导性荨麻疹诊治专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 479-488.
[3]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 慢性自发性荨麻疹达标治疗专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 489-495.
[4]	焦晴晴张晓艳季江. 慢性自发性荨麻疹活动度相关生物学指标的研究进展[J]. 中华皮肤科杂志, 2023, 56(6): 559-562.
[5]	陈奇权杨显杰王文稳梁高澎宋志强. 胆碱能性荨麻疹临床评估工具的开发及应用进展[J]. 中华皮肤科杂志, 2023, 56(6): 563-566.
[6]	米淑宏余艳琴郝金奇李薇张杨贾喜梅黄毓娴孙怀玉石继海. 丘疹脓疱型玫瑰痤疮患者皮肤高频超声联合彩色多普勒血流成像的特征[J]. 中华皮肤科杂志, 2023, 56(6): 540-544.
[7]	张立明肖汀. 慢性自发性荨麻疹的自身免疫发病机制研究进展[J]. 中华皮肤科杂志, 2023, 56(6): 567-570.
[8]	杨娜丽许秋阳吴含文叶雅慧朱吉玲刘晶晶李智铭. [开放获取] 奥马珠单抗治疗慢性荨麻疹的疗效和安全性回顾性分析[J]. 中华皮肤科杂志, 2023, 56(6): 518-524.
[9]	陈奇权孔敏敏杨显杰王欢李健张名望宋志强. [开放获取] 慢性诱导性荨麻疹患者168例过敏原反应性和特应性病史的临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 496-503.
[10]	苏畅隋秀丽刘瑞玲曹毅群姜虹严彩蓉王惠平亓玉青. [开放获取] 奥马珠单抗治疗慢性自发性荨麻疹伴有其他过敏性疾病患者74例临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 512-517.
[11]	王鑫刘丽娟李邻峰. [开放获取] 我国慢性自发性荨麻疹临床特征：基于多家医院问卷调查的流行病学研究[J]. 中华皮肤科杂志, 2023, 56(6): 525-530.
[12]	李丽俏彭聪陈翔李捷. [开放获取] 奥马珠单抗治疗对抗组胺药反应不佳的慢性荨麻疹患者单中心回顾性研究[J]. 中华皮肤科杂志, 2023, 56(6): 504-511.
[13]	贾苇雪李诚让. 中外白癜风诊疗指南及共识比较[J]. 中华皮肤科杂志, 2023, 56(5): 471-475.
[14]	《蕈样肉芽肿治疗中国专家共识》编写专家组. [开放获取] 蕈样肉芽肿治疗中国专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(5): 402-409.
[15]	胡清洁周敏姚煦. 坏疽性脓皮病36例临床特点分析及PARACELSUS评分与Delphi标准的比较[J]. 中华皮肤科杂志, 2023, 56(5): 410-414.

[开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展

Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 15

Metrics

本文评价

推荐阅读 10